+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are studying MK-2214 to see if it can slow brain changes in people with early Alzheimers disease AD, a condition that affects memory, communication, and decision-making. This trial focuses on whether MK-2214 can reduce the spread of tau protein in the brain compared to a placebo, while also assessing the safety and tolerance of the treatment. Participants receive either MK-2214 or a placebo through an intravenous IV infusion every four weeks during the base study period. After completing this period, participants have the choice to continue receiving MK-2214 in an optional open-label extension. The placebo group only receives treatment during the base period. Throughout the study, participants will undergo brain scans, including tau PET imaging, to measure changes in tau protein levels. Researchers will also assess cognitive function and daily living abilities using tools like the Clinical Dementia Rating-Sum of Boxes and Alzheimers Disease Assessment Scale. Safety is monitored by tracking adverse events and treatment discontinuations. The study is expected to last up to approximately 23 months for the base period, with continued treatment during the extension phase.

Age: 50Years - 85YearsAll GendersPhase 2
80 locations
I

Actively Recruiting

Researchers are studying the effectiveness and safety of a combination drug called eloralintide and tirzepatide EloraTZP compared to tirzepatide alone for reducing body weight in adults who have obesity or are overweight and also have type 2 diabetes. This Phase 3 trial aims to understand how these treatments affect weight loss and other health measures over time. Participants will be randomly assigned to receive either EloraTZP or tirzepatide, both given by subcutaneous injection. The study involves a double-blind design, meaning neither participants nor researchers know which treatment is given. The treatment period lasts for about 100 weeks, during which participants receive regular doses and monitoring. During the study, participants will have their body weight and other health indicators, such as waist circumference, blood sugar levels, blood pressure, cholesterol, and quality of life, regularly measured from the start through week 100. Researchers will also monitor safety through laboratory tests and pharmacokinetic assessments. Overall participation in the study lasts about two years, with ongoing evaluations to understand the treatments effects and safety.

Age: 18Years +All GendersPhase 3
75 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of orforglipron in adult women with stress urinary incontinence SUI who are overweight or have obesity. SUI is characterized by leaking urine during activities such as coughing or exercising. This phase 3 study aims to compare orforglipron to a placebo in this specific population. Participants will be randomly assigned to receive either orforglipron or a placebo orally. The study follows a parallel design with double masking and includes two independent groups. Treatment and assessments will occur over approximately 58 weeks, including screening, treatment, and safety follow-up. During the trial, participants will undergo evaluations to measure changes in the frequency of incontinence episodes, body weight, quality of life specific to urinary incontinence, use of continence pads, patient impression of condition, cholesterol levels, and waist circumference from baseline to week 52. Safety monitoring will continue through the follow-up period to assess any treatment-related effects.

Age: 18Years +FEMALEPhase 3
120 locations
E

Actively Recruiting

Researchers are evaluating the effect of a 24-week once daily treatment with Treprostinil Palmitil Inhalation Powder TPIP compared with a placebo in adults with Pulmonary Arterial Hypertension PAH. This Phase 3 study aims to assess the impact of TPIP on exercise capacity and safety in participants with various subtypes of PAH, including idiopathic, heritable, drug-induced, and connective tissue disease-associated PAH. Participants will be randomly assigned to receive either TPIP once daily at a starting dose of 80 micrograms, gradually increased up to a maximum tolerated dose of 1280 micrograms, or a matching placebo for 24 weeks. Both treatments are delivered via oral inhalation using a capsule-based dry powder inhaler device. The study is double-blind and includes parallel groups receiving either the active drug or placebo. Throughout the study, participants will undergo assessments including 6-minute walk tests to measure exercise capacity, evaluations of functional class, and biomarker analysis such as N-terminal pro hormone brain natriuretic peptide levels. Researchers will also monitor symptoms using the PAH-SYMPACT questionnaire, track time to clinical worsening events, and assess heart function through imaging measures. Plasma concentrations of the drug will be collected at various time points. The total participation duration is 24 weeks, with safety and efficacy closely monitored during this period.

Age: 18Years - 75YearsAll GendersPhase 3
39 locations
P

Actively Recruiting

Researchers are studying adults with pulmonary hypertension associated with interstitial lung disease PH-ILD to evaluate the effects of a 24-week daily treatment using Treprostinil Palmitil Inhalation Powder TPIP compared to a placebo. This phase 3, randomized, double-blind, placebo-controlled study aims to assess how TPIP impacts exercise capacity in this group. Participants will receive either TPIP once daily, starting at 80 micrograms and increasing to a maximum tolerated dose of 1280 micrograms, or a placebo inhaled via a capsule-based dry powder inhaler. The treatment period lasts for 24 weeks, and both groups use the same type of inhalation device to maintain blinding. During the study, participants will undergo assessments including the 6-minute walk test to measure exercise capacity and blood tests to track heart-related biomarkers like NT-proBNP. Researchers will monitor clinical worsening events, adverse effects, and plasma drug levels throughout the 24-week treatment. The study is designed to provide detailed information about TPIPs impact on PH-ILD over this period.

Age: 18Years +All GendersPhase 3
186 locations